港股異動 | 中滙集團(0382.HK)漲6%創近2個月新高 機構唱好+明日發中期業績
格隆匯4月19日丨中滙集團(0382.HK)續升6%,2日累計漲幅超12%。現報8.8港元創近2個月新高,總市值94億港元。BNPP法巴(Morningstar晨星)發佈研報上調中滙集團目標價至13港元,對應2022財年盈利的18.8倍PE。基於廣東學校兩個新校區四會校區和新會校區的陸續建成,加上2020年12月四川收購學校四川城市職業學院和四川城市技師學院的業績並表,該行認為中滙集團未來5年的盈利將會有不低於32%的年複合增長。另外,公司將於4月20日(明日)舉行董事會會議審批中期業績,此前預期2021財年上半年經調整純利同比增幅不低於30%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.